颈段及胸上段食管癌调强放疗不同照射方式预后分析  

Prognostic analysis of intensity-modulated radiotherapy for cervical and upper thoracic esophageal carcinoma

作　　者：沈文斌[1] 许金蕊 李曙光[1] 曹彦坤[1] 李幼梅[1] 祝淑钗[1] Shen Wenbin;Xu Jinrui;Li Shuguan;Cao Yankun;Li Youmei;Zhu Shuchai(Department of Radiation Oncology,The Forth Hospital of Hebei Medical University,Shijiazhaung 050011,China)

机构地区：[1]河北医科大学第四医院放疗科,石家庄050011

出　　处：《中华放射肿瘤学杂志》2020年第10期842-848,共7页Chinese Journal of Radiation Oncology

摘　　要：目的分析接受根治性调强放疗(IMRT)±化疗对颈、胸上段食管鳞癌患者的预后,并探讨选择性淋巴结照射(ENI)在其治疗中的意义。方法收集河北医科大学第四医院放疗科接受IMRT±化疗的颈段和胸上段食管鳞癌患者309例进行回顾性研究,分析预后影响因素,并对接受不同照射方式患者进行分组,分析其疗效、不良反应等情况。结果全组患者1、3、5年总生存(OS)率和无进展生存(PFS)率分别为76.7%、37.4%、19.3%和59.7%、27.4%、14.4%,中位数分别为26.8个月和15.5个月。多因素分析结果显示患者性别、cTNM分期、化疗为影响全组患者OS的因素(P=0.003、P<0.001、P=0.022);性别、cTNM分期、照射方式为影响全组患者PFS的因素(P=0.016、P<0.001、P=0.008)。倾向得分匹配后患者1、3、5年OS和PFS分别为77.2%、39.3%、20.0%和62.0%、29.3%、15.4%,中位数分别为27.1个月和18.2个月。多因素分析结果显示患者性别、cTNM分期和化疗为影响其OS的因素(P=0.026、P<0.001、P=0.017);cTNM分期和照射方式为影响其PFS独立性预后因素(P<0.001、P=0.008)。化疗亚组分析显示患者接受3~4周期化疗为佳。患者不良反应均以0-2级为主且可以耐受。结论IMRT±化疗对颈段和胸上段食管鳞癌患者治疗有效;ENI可以提高患者的PFS。Objective To analyze the clinical prognosis of patients with cervical and upper thoracic esophageal squamous cell carcinoma treated with radical intensity-modulated radiotherapy(IMRT)with or without chemotherapy,and to explore the significance of elective lymph node irradiation(ENI).Methods A retrospective analysis was performed on 309 patients with cervical and upper thoracic esophageal squamous cell carcinoma who underwent IMRT with or without chemotherapy in the Department of Radiology,the Fourth Hospital of Hebei Medical University.The prognostic factors were analyzed and patients receiving different irradiation methods were assigned into different group.The curative effect,toxicity and side effects were analyzed among different groups.Results The 1-,3-and 5-year overall survival(OS)and progression-free survival(PFS)were 76.7%,37.4%,19.3%and 59.7%,27.4%and 14.4%,respectively,with median values of 26.8 and 15.5 months.Multivariate analysis showed that gender,cTNM staging and chemotherapy were the prognostic factors affecting the OS(P=0.003,P<0.001,P=0.022),and gender,cTNM stage and radiation mode were the prognostic factors affecting the PFS(P=0.016,P<0.001,P=0.008).After propensity score matching(PSM),the 1-,3-,and 5-year OS and PFS were 77.2%,39.3%,20.0%,and 62.0%,29.3%,and 15.4%,respectively,with median values of 27.1 and 18.2 months.Multivariate analysis showed that gender,cTNM staging and chemotherapy were the prognostic factors affecting the OS(P=0.026,P<0.001,P=0.017);cTNM staging and irradiation mode were the prognostic factors affecting the PFS(P<0.001,P=0.008).A subgroup analysis of chemotherapy showed that patients receiving 3-4 cycles of chemotherapy were preferred.The side effects of the patients were mainly grade 0 to 2,which could be tolerated.Conclusions IMRT combined with or without chemotherapy is an efficacious treatment for patients with cervical and upper thoracic esophageal squamous cell carcinoma;ENI can improve the PFS of patients.

关 键 词：食管肿瘤/鳞癌 食管肿瘤/调强适形放射疗法 食管肿瘤/化学疗法 预后 

分 类 号：R735.1[医药卫生—肿瘤] R730.55[医药卫生—临床医学]